ATRA on Nasdaq
Atara Biotherapeutics, Inc.
Clinical-stage biotechnology company.1
Price unavailable
Last updated Oct 16, 2026.
Overview
2012Founded1
Compare with Monte Rosa Therapeutics, Acorda Therapeutics or Agenus, or pick any stock.
- TickerATRA on Nasdaq1
- IndustryCellular therapy and transplantation, autoimmune disease, biotechnology, multiple sclerosis, oncology1
- HeadquartersSouth San Francisco1
- Websitewww.atarabio.com
- Legal formDelaware corporation1
- Incorporated inDE3
- Business address1280 Rancho Conejo Blvd, Thousand Oaks, Ca 913203
- Filer categoryNon-accelerated filer, Smaller reporting company3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development31¢$37.4M
- Other costs39¢$46.8M
- Interest3¢$3.8M
- Income tax0¢$31.0K
- Profit27¢$32.7M
Out of $120.8M in revenue.4
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Commercialization revenue | $120.8M | $128.9M |
| Total revenue | $120.8M | $128.9M |
| Cost of commercialization revenue | $21.2M | $21.0M |
| Research and development expenses | $37.4M | $151.5M |
| General and administrative expenses | $26.3M | $39.9M |
| Total costs and operating expenses | $84.9M | $212.4M |
| Loss from operations | $35.9M | -$83.4M |
| Interest income | $683.0K | $2.1M |
| Interest expense | -$3.8M | -$4.6M |
| Other income (expense), net: | -$34.0K | $528.0K |
| Total other income (expense), net | -$3.1M | -$2.0M |
| Loss before provision for (benefit from) income taxes | $32.7M | -$85.4M |
| Provision for (benefit from) income taxes | $31.0K | -$12.0K |
| Net loss | $32.7M | -$85.4M |
| Unrealized gain (loss) on available-for-sale securities | -$7.0K | $212.0K |
| Comprehensive loss | $32.7M | -$85.2M |
| Basis net loss per common share | $2.61 | -$11.41 |
| Diluted net loss per common share | $2.57 | -$11.41 |
| Basic weighted-average shares outstanding | 12.5M shares | 7.5M shares |
| Diluted weighted-average shares outstanding | 12.7M shares | 7.5M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $8.5M | $25.0M | |
| Short-term investments | $0 | $17.5M | |
| Restricted cash | $0 | $146.0K | |
| Accounts receivable | $1.3M | $1.5M | |
| Inventories | $0 | $10.7M | |
| Other current assets | $2.5M | $10.1M | |
| Total current assets | $12.2M | $64.9M | |
| Property and equipment, net | $73.0K | $1.3M | |
| Operating lease assets | $7.1M | $39.8M | |
| Other assets | $886.0K | $3.1M | |
| Total assets | $20.2M | $109.1M | |
| Accounts payable | $127.0K | $4.4M | |
| Accrued compensation | $1.3M | $6.6M | |
| Accrued research and development expenses | $82.0K | $8.0M | |
| Deferred revenue | $716.0K | $95.1M | |
| Liability related to the sale of future revenues - current portion | $9.8M | $382.0K | |
| Other current liabilities | $3.0M | $20.2M | |
| Total current liabilities | $14.9M | $134.6M | |
| Operating lease liabilities - long-term | $9.3M | $29.9M | |
| Liability related to the sale of future revenues - long-term | $32.7M | $38.6M | |
| Other long-term liabilities | $1.8M | $3.3M | |
| Total liabilities | $58.7M | $206.4M | |
| Common stock - $0.0001 par value, 500,000 shares authorized as of December 31, 2025 and 2024, respectively; 7,324 and 5,859 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $1.0K | $1.0K | |
| Additional paid-in capital | $2.0B | $2.0B | |
| Accumulated other comprehensive income | $1.0K | $8.0K | |
| Accumulated deficit | -$2.0B | -$2.1B | |
| Total stockholders' equity (deficit) | -$38.5M | -$97.3M | $99.2M |
| Total liabilities and stockholders' equity (deficit) | $20.2M | $109.1M | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 7.3M shares | 5.9M shares | |
| Common stock, shares outstanding | 7.3M shares | 5.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net income (loss) | $32.7M | -$85.4M |
| Stock-based compensation expense | $9.8M | $27.0M |
| Non-cash operating lease expense | $5.0M | $12.1M |
| Depreciation and amortization expense | $2.1M | $5.1M |
| Accretion of liability related to sale of future revenues | $3.6M | $4.1M |
| Amortization (accretion) of investment premiums (discounts) | $259.0K | -$240.0K |
| Loss on impairment of lease right-of-use asset | $4.1M | $0 |
| Gain on derecognition of lease liabilities upon contract assignment | -$3.8M | $0 |
| Other non-cash items, net | $94.0K | -$402.0K |
| Accounts receivable | $229.0K | $32.6M |
| Inventories | $10.7M | -$4.4M |
| Other current assets | $6.2M | -$1.2M |
| Other assets | $15.0K | $19.0K |
| Accounts payable | -$4.2M | $687.0K |
| Accrued compensation | -$5.3M | -$4.9M |
| Accrued research and development expenses | -$7.9M | -$9.4M |
| Other current liabilities | -$4.5M | -$12.5M |
| Deferred revenue | -$94.4M | -$20.3M |
| Operating lease liabilities | -$5.5M | -$11.1M |
| Other long-term liabilities | $1.0K | -$462.0K |
| Net cash used in operating activities | -$50.9M | -$68.7M |
| Purchases of short-term investments | -$7.9M | -$19.7M |
| Proceeds from maturities and sales of short-term investments | $25.1M | $28.5M |
| Purchases of property and equipment | $0 | -$246.0K |
| Proceeds from sale of property and equipment | $948.0K | $0 |
| Net cash provided by investing activities | $18.1M | $8.6M |
| Proceeds from sale of common stock and pre-funded warrants in registered direct offerings, net | $14.8M | $50.6M |
| Proceeds from issuance of common stock through ATM facilities, net | $1.5M | $9.3M |
| Proceeds from employee stock awards | $35.0K | $230.0K |
| Principal payments on finance lease obligations | -$250.0K | -$892.0K |
| Other financing activities, net | -$1.0K | -$7.0K |
| Net cash provided by financing activities | $16.1M | $59.3M |
| Decrease in cash, cash equivalents and restricted cash | -$16.7M | -$811.0K |
| Cash paid for interest | $286.0K | $685.0K |
| Cash paid for income taxes | $190.0K | $24.0K |
Timeline
- 2012Founded Founded1
Recent filings
- Sep 4, 20264
- Aug 26, 20264
- Aug 26, 2026144
- Aug 14, 2026SCHEDULE 13G/A
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Jul 24, 2026SCHEDULE 13D/A
- Jul 24, 20264 OWNERSHIP DOCUMENT
- Jul 6, 20263
- Jun 26, 20268-K
- Jun 15, 20263
- Jun 15, 20264
- Jun 12, 20268-K CURRENT REPORT
- Jun 12, 2026S-8 REGISTRATION STATEMENT
- Jun 11, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.atarabio.com1
- WikidataQ21874220
- SEC EDGARCIK 1604464
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11